乳房及乳房外Paget病临床病理分析及相关蛋白表达的研究

发布时间：2018-04-22 17:04

本文选题：乳房Paget病 + 乳房外Paget病　；参考：《吉林大学》2010年博士论文

【摘要】： 目的:检测相关蛋白表达,探讨PD细胞起源及肿瘤生物治疗;分析临床病理及治疗参数与预后和复发关系,指导治疗前正确评估,降低复发率。方法:回顾性对比分析62例PD的临床病理及治疗资料。免疫组化方法检测ER,PR,AR,E-cad,GCDFP-15,MUC5AC,HER-2/neu蛋白表达,结果采用半定量分析。数据进行统计学分析,P0.05认为有统计学意义。结果:触及乳腺肿块、腋窝淋巴结肿大、乳腺X线可疑征象及伴有IDC与MPD患者预后有关;肿瘤的侵润生长深度及肿瘤边界清晰与否与EMPD复发有关;MPD组肿瘤细胞主要表现为垂直生长趋势,EMPD组肿瘤细胞主要表现为水平播散生长趋势。所有病例均表达CK7,MUC1;ER,PR,AR,GCDFP-15,MUC5AC,HER-2/neu,E-cad在MPD组表达分别为4.8%,0%,35.7%,50%,11.9%,88.1%,64.3%;在EMPD组的表达分别为0%,0%,80%,80%,60%,50%,45%。结论:MPD及EMPD本质为原发表皮内汗腺癌,两种疾病生物学行为不同,抗雄性激素及曲妥珠单抗的治疗可作为一种辅助治疗方法;乳腺肿块、腋窝淋巴结肿大、乳腺X线可疑征象及伴有IDC可作为MPD患者预后不良的危险因素;肿瘤的侵润生长深度及肿瘤边界清晰与否可作为影响EMPD复发的危险因素。
[Abstract]:Objective: to detect the expression of related proteins, to investigate the origin of PD cells and tumor biotherapy, to analyze the relationship between clinicopathological parameters and prognosis and recurrence, to guide the correct evaluation before treatment and to reduce the recurrence rate. Methods: the clinicopathological and therapeutic data of 62 cases of PD were analyzed retrospectively. Immunohistochemical method was used to detect the expression of HER-2 / neu protein in AR-AR-E-cadGCDFP-15 / MUC5ACHER-2 / neu protein. The results were semi-quantitatively analyzed. The data were statistically analyzed and considered statistically significant (P0.05). Results: involvement of breast masses, enlargement of axillary lymph nodes, suspicious signs of mammography and prognosis of patients with IDC were related to the prognosis of patients with MPD. The depth of tumor invasion and the clarity of tumor boundary were related to the recurrence of EMPD. The tumor cells in EMPD group showed vertical growth trend and horizontal spreading growth trend. All cases expressed CK7C5ACHER-2neuE -cad in the MPD group, the expression of HER-2neuE-cad in the MPD group was 4.80.35. 7%, and the expression in the EMPD group was 11.988. 1 and in the EMPD group, the expression was respectively 0 / 0 / 80 / 8080 / 80 / 60 and 50 / 45 / 4545, respectively, in the EMPD group, the expression of HER-2NU E-cad in the MPD group was 4.890 / 55.The expression of HER-2neuE-cad in the EMPD group was 4.80%, respectively. Conclusion the biological behavior of the two diseases is different. The treatment of anti-androgen and tritozumab can be used as an adjuvant treatment for breast mass, axillary lymph node enlargement, breast mass, axillary lymphadenopathy, breast mass, axillary lymphadenopathy, breast mass, axillary lymphadenopathy, breast mass, axillary lymph node enlargement, The suspicious signs of mammography and IDC may be the risk factors for the poor prognosis of MPD patients, and the depth of tumor invasion and the clarity of tumor boundary may be the risk factors for the recurrence of EMPD.
【学位授予单位】：吉林大学
【学位级别】：博士
【学位授予年份】：2010
【分类号】：R739.5

【引证文献】